Combination treatment of vertebral metastases using image-guided percutaneous radiofrequency ablation and vertebroplasty: a case report

BACKGROUND: We describe a case of vertebral metastases treated with a combination of percutaneous radiofrequency ablation (RFA) and vertebroplasty in a single session. CASE DESCRIPTION: A 45-year-old female with recently diagnosed metastatic non-small cell lung cancer was referred for consideration of vertebroplasty after having several weeks of back pain. Computed tomography and magnetic resonance imaging scans of the thoracic spine revealed metastatic lesions at the T9 and T12 bodies. Radiofrequency ablation was performed using a starburst array electrode (Rita Medical Systems, Mountain View, Calif). The metastatic lesion in the T9 vertebral body measured 1.5 x 1.5 cm and was heated to 100 degrees C for 5 minutes. Vertebroplasty was then performed on this lesion as well as a lesion at T12 with no complications. The patient was discharged home the same day without complaints. CONCLUSION: Radiofrequency ablation and vertebroplasty are minimally invasive procedures that can be used in combination to treat spinal metastases. The pain relief from these treatments is often immediate. RFA can also be used to minimize procedure-related complications during the vertebroplasty. In properly selected patients, RFA may also increase the duration of local spinal stabilization afforded by the vertebroplasty alone. Long-term studies are warranted to assess the efficacy and durability of this unique approach.     

Prediction of antimalarial activity of some cyclic peroxy ketals using physico-chemical and topological indices

This study is based on modeling the anti-malarial activity (log IC₅₀/nm) of 20 cyclic peroxy ketals using topological and physicochemical parameters. The multiple regression analysis reveals that the five-parametric model containing MW, ST, χ _eq, ⁰ χ ^v, IP₂ as correlating parameters is the best for modeling the activity of the compounds under present study. The cross-validated parameters have been calculated by LOO cross-validation procedure for validation of proposed model.     

Undifferentiated Tumors: An Immunohistochemical Analysis on Biopsies

Immunohistochemical staining was performed on 145 biopsies with a diagnosis of undifferentiated or poorly differentiated tumor in order to classify them into lymphoid, epithelial, or mesenchymal in origin. It was possible to arrive at a histogenetic diagnosis on immunostaining in 85.5% of cases. Immunostaining confirmed the diagnosis in 32.4% and contributed to diagnosis in 53.1%. Malignant lymphoma was the most common diagnosis (35.9%), followed by carcinoma (23.4%). A panel of antibodies consisting of anti-common leucocyte antigen (LCA), anti-epithelial membrane antigen (EMA), anti-cytokeratin (CK), anti-low to intermediate molecular weight cytokeratin (CAM 5.2), anti-S-100 protein (S-100), and anti-vimentin (VM) may resolve, to a large extent, some of the common diagnostic problems. © 1994 Wiley-Liss, Inc.     

Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey

Urotensin-II (U-II) and its receptor (UT) represent novel therapeutic targets for management of a variety of cardiovascular diseases. To test such hypothesis, it will be necessary to develop experimental animal models for the manipulation of U-II/UT receptor system. The goal of this study was to clone mouse and primate preproU-II and UT for pharmacological profiling. Monkey and mouse preproU-II genes were identified to encode 123 and 125 amino acids. Monkey and mouse UT receptors were 389, and 386 amino acids, respectively. Genomic organization of mouse genes showed that the preproU-II has four exons, while the UT receptor has one exon. Although initially viewed by many exclusively as cardiovascular targets, the present study demonstrates expression of mouse and monkey U-II/UT receptor mRNA in extra-vascular tissue including lung, pancreas, skeletal muscle, kidney and liver. Ligand binding studies showed that [125I]h U-II bound to a single sites to the cloned receptors in a saturable/high affinity manner (Kd 654+/-154 and 214+/-65 pM and Bmax of 1011+/-125 and 497+/-68 fmol mg-1 for mouse and monkey UT receptors, respectively). Competition binding analysis demonstrated equipotent, high affinity binding of numerous mammalian, amphibian and piscine U-II isopeptides to these receptors (Ki=0.8 - 3 nM). Fluorescein isothiocyanate (FITC) labelled U-II, bound specifically to HEK-293 cells expressing mouse or monkey UT receptor, confirming cell surface expression of recombinant UT receptor. Exposure of these cells to human U-II resulted in an increase in intracellular [Ca2+] concentrations (EC50 3.2+/-0.8 and 1.1+/-0.3 nM for mouse and monkey UT receptors, respectively) and inositol phosphate (Ip) formation (EC50 7.2+/-1.8 and 0.9+/-0.2 nM for mouse and monkey UT receptors, respectively) consistent with the primary signalling pathway for UT receptor involving phospholipase C activation.     

VAD followed by VMCP: an alternative regimen for multiple myeloma

In patients with multiple myeloma, a good complete response rate and disease-free survival may be achieved with sequential chemotherapy using VAD and VMCP, which is an alternative effective and less expensive treatment regimen. This regimen thus assumes particular significance in developing nations like India, where the majority of patients with myeloma cannot afford the cost of high-dose chemotherapy with stem cell rescue.     

Kala-azar-new developments in diagnosis and treatment

Kala-azar is an endemic, disease in many parts of India. Traditionally diagnosis of this disease was based on demonstrating the parasites in various tissues like bone marrow or splenic aspirates. However, lack of high sensitivity of these methods led to the use of various immunodiagnostic methods in the diagnosis of kala-azar. Antigen detection and polymerase chain reaction to detect parasitic DNA have been found to be useful in patients with an underlying immunosuppressive disease like AIDS. For treating kala-azar, pentavalent antimonial compounds are still the first-line agents. However, due to increasing resistance to this agent, many patients at present requie other drugs including amphotericin B and pentamidine. Toxic effects of these second-line agents have led to development of drug dellvery systems like liposomal amphotericin B, which has shown uniform efficacy in clinical trials. Combining stibogluconate with either paromomycin or interferon-γ has also been shown to be useful in many patients with drug-resistant kala-azar.     

Late magnetic resonance imaging features of leukoencephalopathy in children with central nervous system tumours following high-dose methotrexate and neuraxis radiation therapy

High-dose methotrexate (HDMTX) is used increasingly to treat children with central nervous system (CNS) tumours. Although the neuro-imaging features of leukoencephalopathy associated with systemic or intrathecal methotrexate administered after cranial radiation have been well described, the extent to which the sequencing of HDMTX prior to cranial radiation in infants and children predisposes to late neuroradiological features of leukoencephalopathy is unknown. This report describes the National Cancer Institute (NCI) toxicity grade of leukoencephalopathy based on magnetic resonance imaging (MRI) findings in all patients who survived 4 or more years after treatment on an earlier phase II study. These patients, with newly diagnosed CNS embryonal tumours, were in the age range 3.5-14.2 years (median 6.9 years) at diagnosis, and received four courses of pre-irradiation combination chemotherapy, including HDMTX 8 g/m(2). Following completion of the 'up-front' phase II study, all patients received conventionally fractionated whole brain doses of 36-50.4 Gy. The radiation dose and treatment volumes were determined individually according to the primary tumour location and results of extent of disease evaluations. The most recent MRI brain scans, obtained 4.0-10.5 years (median 6.5 years) after radiation therapy and comprising a minimum of T1, T1 following gadolinium and T2 sequences, were reviewed centrally to assess the neuroradiological grade of leukoencephalopathy, based on the NCI Common Terminology Criteria for Adverse Events, v3.0. Grade I changes (mild increase in subarachnoid space, and/or mild ventriculomegaly, and/or small/focal T2 hyperintensities) were evident in 8 of the 12 patients and grade II changes (moderate increase in subarachnoid space and/or moderate ventriculomegaly, and/or focal T2 hyperintensities extending to the centrum ovale) were found in the remaining 4. In conclusion, treatment with multiple courses of HDMTX prior to 36-50.4 Gy cranial radiation did not result in moderate to severe MRI features of leukoencephalopathy. Future studies in paediatric neuro-oncology patients, involving HDMTX combined with prospective neuropsychological evaluations appear justified.